Livforsakringsbolaget Skandia Omsesidigt raised its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.7% during the first quarter, Holdings Channel.com reports. The fund owned 68,130 shares of the medical research company’s stock after purchasing an additional 10,752 shares during the quarter. Amgen accounts for approximately 1.0% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 22nd largest position. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Amgen were worth $23,950,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of AMGN. High Note Wealth LLC increased its holdings in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares during the period. TAGStone Capital Inc. lifted its holdings in Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after buying an additional 28 shares during the period. Verus Capital Partners LLC lifted its holdings in Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after buying an additional 28 shares during the period. Destination Wealth Management grew its position in shares of Amgen by 2.1% in the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after buying an additional 29 shares during the last quarter. Finally, Breakwater Capital Group grew its position in shares of Amgen by 1.4% in the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after buying an additional 29 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently commented on AMGN. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $350.00 price target on shares of Amgen in a report on Monday, July 6th. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a report on Friday, June 5th. Finally, Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $356.62.
Amgen Price Performance
Shares of AMGN stock opened at $355.25 on Wednesday. The business’s fifty day moving average is $345.60 and its 200 day moving average is $349.81. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The stock has a market cap of $191.73 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 3.56 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $391.29.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the firm posted $4.90 earnings per share. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts expect that Amgen Inc. will post 22.31 EPS for the current fiscal year.
Insider Activity
In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by insiders.
Key Stories Impacting Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: BMO Capital reiterated its Buy rating on Amgen, reinforcing a bullish stance from one analyst firm. BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
- Positive Sentiment: One report argued Amgen could be as much as 47% undervalued after the Enbrel price-cap ruling, suggesting the stock may have meaningful upside if that view proves correct. Amgen (AMGN) Stock May Be 47% Undervalued After Enbrel Price Cap Ruling
- Neutral Sentiment: Amgen remains a heavily watched stock, and several articles focused on valuation comparisons and broader competitive positioning rather than a new company-specific catalyst. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
- Neutral Sentiment: Guggenheim raised its price target slightly to $343 while keeping a Neutral rating, signaling limited upside in the firm’s view. Amgen price target raised by Guggenheim
- Negative Sentiment: Bank of America Securities reiterated a Sell rating and said Amgen’s near-term growth remains limited, with the stock trading above its newly raised price target of $312. Analyst Maintains Sell on Amgen as Shares Trade Above Newly Raised $312 Price Target and Near-Term Growth Remains Limited
About Amgen
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
- Five stocks we like better than Amgen
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
